SOCIETÀ ITALIANA DI CANCEROLOGIA

CONSIGLIO DIRETTIVO (2020-2022)

PRESIDENTE
NICOLA NORMANNO
NAPOLI

PRESIDENTE ELETTO
MAURIZIO D'INCALCI
MILANO

PAST PRESIDENT
GABRIELLA SOZZI
MILANO

CONSIGLIERI

PAOLA ALLAVENA
MILANO

GUSTAVO BALDASSARRE
AVIANO PN

FABRIZIO BIANCHI
SAN GIOVANNI ROTONDO FG

GIOVANNI BLANDINO
ROMA

ANTONINO BRUNO
MILANO

PAOLA CHIARUGI
FIRENZE

FEDERICA DI NICOLANTONIO
TORINO

CONSIGLIERI UNDER 35

ILARIA GUERRIERO
ARIANO IRPINO AV

ERICA TORCHIARO
TORINO

General Information on SIC meeting

The Italian Cancer Society (**SIC**), founded in 1952, is the oldest Italian association of **researchers** working in the field of preclinical, translational and clinical **oncology**.

The Society aims at promoting the progress of **cancer research** both in the **experimental** field and in the **clinical** and social ones.

To this aim, SIC supports and facilitates scientific collaborations, creating **synergies** between biomedical researchers of different expertise in oncology.

SIC has established strong relations with similar national and international associations, such as **AIOM**, **EACR** and **AACR**, to promote together the advancement of knowledge.

One of the main features that characterizes of SIC is that we strongly believe in the strength of **new generations**.

For this reason, we have always paid particular attention to the **training** and professional growth of **young** researchers working in the field.

The main appointment in which SIC activities are made explicit is the **Annual Meeting** that in 2022 will be at its 62nd edition.

The meeting is a moment of particular relevance in the life of the Society.

In general, it is the occasion in which cancer researchers from all disciplines and from all Italian regions gather together, share **new research results** and plan **future perspectives**.

We believe that **the 2022 Annual Meeting** will represent a turning point of SIC activities, after the two years of stop imposed by the COVID pandemic.

For this reason, we expect a massive participation of Italian and international cancer researchers.

To facilitate a very large participation we decided to hold the **62nd Meeting**, for the first time, in **Venice.**

Venice is certainly one of the most beautiful and famous Italian city and it is very **well connected** to the rest of Italian cities, both by train and by plane.

To meet the high expectations of SIC members, we are planning a **scientific program of outstanding quality,** also thanks to the active support of the European Cancer Society (**EACR**) and the Italian Association of Medical Oncology (**AIOM**).

Based on SIC previous meetings, we anticipate the registration of at least 300 attendees, in presence.

SIC

62nd annual Meeting of the Italian Cancer Society

THE DATE:

November

16, 17, 18

2022

HOSTING CITY:

VENICE

CONGRESS SITE:

PLENARY ROOM:

350 seats

10 ROOMS

for satellite

symposium

MODE:

On site

+

Virtual

62nd annual Meeting of the Italian Cancer Society

THE TITLE:

The exciting path from preclinical research to clinical application

62nd annual Meeting of the Italian Cancer Society

The exciting path from preclinical research to clinical application

VENICE November 16-18, 2022

PARTNERS

EACR European Association for Cancer Research

AIRC

AIOM Associazione Italiana di Oncologia Medica

SCIENTIFIC COORDINATORS

Gustavo Baldassarre

Head of the Molecolar Oncology Unit,

Division of Molecular Oncology,

Centro di Riferimento Oncologico di Aviano (CRO),

IRCCS, National Cancer Institute (NCI), Aviano (PN), Italy

Fabio Puglisi

Head of the Department of Medical Oncology,

Centro di Riferimento Oncologico di Aviano (CRO),

IRCCS, National Cancer Institute (NCI), Aviano (PN), Italy

Professor of Medical Oncology,

Head of the School of Medical Oncology,

Department of Medicine, University of Udine, Italy.

LOCAL SCIENTIFIC AND ORGANIZING COMMITTEE

Local scientific and organizing committee will be released soon and will include **basic**, **translational** and **clinical researchers** from different disciplines, operating in the **oncology field** in:

CRO of Aviano, IRCCS

IOV IRCCS, Università di Padova

Università di Udine

Università di Trieste

Università Ca foscari di Venezia

Università SISSA di Trieste

2022 PROGRAM

The 2022 Scientific Program

In the last few years we have witnessed, as never before in oncology, the rapid translation of preclinical research into clinical application.

This is due not only to the fast approval of new targeted and immune compounds, but also to the **compelling necessity to properly and thoroughly characterize** the molecular alterations of human tumors, in order to provide each patients with the most appropriate treatment.

These rapid changes urge us to **bring together preclinical and clinical researchers** to discuss clinical cases and therapeutic opportunities in *ad hoc* **multidisciplinary boards** (*e.g. molecular tumor board, MTB*) that are now being established in Italy, both in cancer centers and at regional levels.

This will be one of the main **focus** of the **62nd SIC Annual Meeting** that we therefore named "**The exciting path from preclinical research to clinical application**".

2022 PROGRAM

The **meeting** will be of **interest for both preclinical and clinical researchers** , working in different disciplines of cancer research.

In light of this broad attendance, we will design scientific sessions in which the most actual unmet needs will be discussed from different perspectives.

Based on these principles, the **opening** and the **closing lectures** will be held by world reknown **preclinical** and **clinical researcher**, respectively.
If they will accept, we plan to have with us scientists like **Prof. Chris Lord** of Cancer Research UK The Institute of Cancer Research & Breast Cancer Now Toby Robins Research Centre of London and **Prof. Fabrice Andrè** Director of Research at the Institute Gustave Roussy, or personalities of equivalent scientific level.

Over a **two days and half** time frame, we will have **6 plenary scientific sessions** of approximately 1.5 hours, and **4 poster discussion sessions** , mostly dedicated to young researchers.

TOPICS

The 2022 Topics

We are aware that new **targeted therapies** could be very active in oncology but also that tumors evolve and **resistance mechanisms** to these agents emerge.

This is particularly true for drugs targeting oncogenic surface **receptors** that are now used in different human cancers, like lung breast, colon, head and neck, thyroid, melanoma, or even in an agnostic way, based on the presence of specific molecular alterations.

For this reason, we anticipate that one the sessions will be dedicated to "**Mechanisms of activity and resistance to drugs targeting surface receptors**" in which we discuss of the new ways to block tumors driven by alterations in genes like ALK, ROS, NTRK, EGFR, FGFR, HER2, c-KIT etc.
We will also discuss which could be the new approaches to identify and overcome resistance to these agents.

In this context, the use of new **drug-conjugated antibodies** will be thoroughly discussed.

TOPICS

Pathways of **DNA damage and repair** are active fields of clinical and preclinical investigation and we now have many active compounds (e.g. inhibitors of PARP, ATR, WEE1 etc.) in clinical use or investigated in dedicated clinical trials, alone or in conjunction with chemo- and targeted or immune therapies.

How DNA damage is sensed and repaired and which are the mechanisms of action of drugs acting on the DNA repair machinery?

How they can be combined with chemo- targeted- and immuno-therapies?

Which are the most novel advancement exploring possible way to overcome resistance?

These will likely be the focus of a dedicated session "**New insights in DNA damage and repair mechanisms**".

TOPICS

Enormous advancements have been also observed in the development and use of **radiotherapy** in different human pathologies and the interplay between radiotherapy and chemo- targeted- and immuno-therapies.

It is definitely the time to better define molecular markers that could predict when it is better to use **photons** compared to **protons** or **electrons** to treat patients, which is biology subtended to each type of treatment and when and why the **combination therapies** could be specifically active.

Emerging evidence also suggest that **radiotherapy** could potentiate the effects of **immunotherapy** in specific tumor setting. How we can identify patients that might benefit most form specific association?

We aim to discuss these topics in a session dedicated to "**Radiotherapy and immunotherapy: the new liaison**".

TOPICS

All these new therapeutic opportunities should be discussed in dedicated multidisciplinary teams.

We are facing a scientific and technological revolution, in which massive data come from genomic, epigenomic, transcriptomic, proteomic, metabolomic, radiomic studies, obtained from primary tumor masses, single cells and/or biological fluids and **could and should help physicians in choosing the best therapeutic options**.

The use of **bioinformatic** and **artificial intelligence applied to clinical** needs will be instrumental in the next year to win these challenges and therefore the cancer research community need to be prepared to drive and govern this transition.

A dedicated session on "**Precision Oncology in the era of Molecular Tumor Boards**" will discuss about these new challenges in the application of OMICS techniques to the analyses of human tumor specimens and liquid biopsies.

TOPICS

Covid pandemic has profoundly and negatively impacted on care of cancer patients and on cancer research.

Yet, on the other side, it has demonstrated how joint public and private efforts and willingness can extremely accelerate the process of designing, testing, producing and distributing an effective vaccine.

It has also proved that RNA manipulation and metabolism has an enormous potential, not only in the diagnostic but also in the therapeutic field.

Further, the Italian next generation renaissance plan, **PNRR** ,has evidenced the necessity to build a **National Center** dedicated to the development of gene therapy applied to the treatment of cancer or hereditary diseases and **RNA-based technologies** that should represent a future excellence in Eu.

Therefore, a session will be dedicated to the most promising advancements in "**RNA metabolism in tumor progression and treatment**", in which we will discuss the regulation of RNA transcription and splicing in human tumors and if and how RNA vaccination could represent a strategy to treat cancer patients.

TOPICS

Finally, we will have a joint session with the medical oncologists association dedicated to the most relevant advancements in the treatment of breast and ovarian cancer patients.

In the **AIOM/SIC joint session: "New molecular targets in women tumors"**, we will discuss the pros and the cons of the new agents that, in the last few years, have been introduced in the clinical practice, like CDK4/6, PI3K or PARP inhibitors or drug-conjugated antibodies.

Which are the challenges we are facing in their use in clinic? And how could we deal with emergence of resistance mechanisms? How can we identify the responding patients, which are the preclinical models we can use?

These are only some of the questions and topics that we will try to respond and cover during this joint session.

TOPICS

As mentioned, in the mission of our Society there is the objective to stimulate the scientific growth of **young researchers**.

To this aim, we will organize **four poster sessions** , in which the speakers will be selected among the **best abstracts** submitted in the areas of 1)Tumor immunology and microenvironment, 2)Cancer genetics, epigenetics and tumor progression, 3)Novel therapeutic approaches and drug resistance, 4)Cancer biomarkers and precision medicine.

Last, but not least, the Society is open to **meet the Industry** on specific aspects of common interest. For this reason we are open in identifying specific topics to be discussed in **dedicated satellite symposiums**, possibly inviting world reknown scientists in the field.

TOPICS

Mechanism of activity and resistance to drugs targeting surface receptors, such as RET/ALK/ROS/NTRK/EGFR/FGFR/HER2

Patologie:
Polmone, Mammella, Agnostico, CRC, Melanoma

Mechanism of response and resistance to drugs targeting the DNA repair machinery

Patologie:
Mammella, Ovaio, Prostata, Pancreas, Agnostico

Joint Session AIOM/SIC
New molecular targets in women Tumors

Patologie:
Mammella, Ovaio

Precision Oncology in the era of Molecular Tumor Board: Apply OMICS techniques to patients' management

Patologie:
Agnostico

RNA metabolism in tumor progression and treatment

Patologie:
Agnostico

Radiotherapy and immunotherapy: the new liaison

Patologie:
CRC, tumori testa-collo, agnostico

Siamo aperti ad organizzare mini-simposi satellite sponsorizzati, su argomenti specifici, di interesse comune.

PARALLEL SESSIONS

1
Tumor immunology and microenvironment

2
Cancer genetics, epigenetics
and tumor progression

3
Novel therapeutic approaches
and drug resistance

4
Cancer biomarkers and precision medicine

CME CREDITS

CME CREDITS

The event will be accredited for the
following Professions and Disciplines:
Medical Surgeon (Disciplines: Clinical Pathology, General Medicine (Family Doctors), Haematology, Internal Medicine, Medical Genetics, Nuclear Medicine, Oncology, Pathological Anatomy, Pharmacology and Clinical Toxicology, Radiology, Radiotherapy);
Biologist,
Pharmacist,
Chemist (Discipline: Analytical Chemistry);
Physicist (Discipline: Health Physics);
Veterinary.

MEETING OPEN ALSO TO*

Biotechnology,
Informaticians,
Bioinformatics

(*) no CME credits

GENERAL INFORMATION

OFFICIAL LANGUAGE:
English

CONGRESS VENUE: Venice

SIC SECRETARIAT
Società Italiana di Cancerologia
Via Giacomo Venezian, 1
20133 Milano
sic@istitutotumori.mi.it
www.cancerologia.it

ORGANIZING SECRETARIAT
Meeting srl
Via Villalta, 32 – 33100 Udine
Tel. 0432 1790500
sic2022@meetingsrl.eu
www.meetingsrl.eu

REGISTRATION FEES

On Site	Virtual
SIC MEMBER:	**SIC MEMBER:**
420€ Early 500€	150€ Early 200€
JOUNG <35 SIC	**JOUNG <35 SIC**
280 € Early 330€	120€ Early 150€
NON MEMBER	**NON MEMBER**
500€ Early 600€	200€ Early 250€
JOUNG < 35	**JOUNG < 35**
380€ Early 400€	150€ Early 200€

62nd annual Meeting of the Italian Cancer Society

The exciting path from preclinical research to clinical application

VENICE November 16-18, 2022